What is Survodutide 5MG & 10MG

Survodutide 5MG & 10MG is a synthetic dual-receptor agonist targeting both GLP-1 and Glucagon receptors, studied in research for its powerful effects on weight loss and the resolution of severe hepatic steatosis. It is intended exclusively for research use.

Regarding its chemical identity, Survodutide has a molecular formula of C175H269N45O55 and a molecular weight of ~3900 g/mol. Its reported canonical sequence is Synthetic Dual Agonist Analogue. A confirmed CAS number is not available in open primary reference sources and is therefore omitted.

Its synonyms include Survodutide.

Product for research use.

Mechanism of action of Survodutide

Survodutide activates GLP-1 receptors to suppress appetite and delay gastric emptying, while simultaneously activating Glucagon receptors. The glucagon activation specifically drives hepatic lipolysis (fat burning within the liver) and increases overall metabolic energy expenditure.

Pharmacokinetics and pharmacodynamics of Survodutide

Engineered for extended systemic exposure, it supports once-weekly administration in in vivo models. The molecule is balanced to ensure that the glucagon-induced hepatic glucose output is offset by the GLP-1-induced insulin secretion, preventing hyperglycemia.

Scientific evidence on Survodutide

The available evidence on Survodutide is preliminary and largely inconclusive, and should be interpreted with caution. The literature describes it as having been investigated for multiple indications in preclinical models.

Currently researched heavily by Boehringer Ingelheim. In mid-stage clinical trials, it demonstrated up to 19% body weight loss and, more importantly, unprecedented rates of resolution for Non-Alcoholic Steatohepatitis (NASH) without worsening fibrosis.

Survodutide applications in research

Ideal for (research context):
– In vitro and preclinical studies of its specific receptor pathways.
– Investigation of tissue repair, cell proliferation, and functional restoration in laboratory models.
– Comparative work with related peptides.

Not applicable for:
– clinical, diagnostic or therapeutic use.
– Any administration to humans or animals outside of an authorized research protocol.

Product for research use.

Survodutide protocols in preclinical studies

The literature consulted does not include numerical doses from studies that can be cited for Survodutide, so no trial schemes or quantities are specified.

The presentations of this product (5MG & 10MG) refer only to the amount of lyophilized peptide per vial (or volume for liquids) and do not constitute a dosage recommendation. The design of any protocol, including concentrations and working volumes, is the responsibility of the researcher, based on their experimental objectives and the relevant primary literature.

Information provided exclusively for research purposes.

Reconstitution and manipulation of Survodutide

As a general guideline for laboratory handling, lyophilized peptides such as Survodutide are usually reconstituted with bacteriostatic water (sterile water with approximately 0.9% benzyl alcohol).

Add the solvent slowly down the side of the vial, letting it run over the lyophilized powder; avoid injecting the stream directly onto the powder.
Do not shake: gently rotate the vial until completely dissolved.
Adjust the solvent volume according to the desired working concentration, considering the 5MG & 10MG contents of the vial.

These guidelines are for general technique and do not replace the internal procedures of each laboratory.

Survodutide Stability and Storage

As a standard laboratory handling procedure for peptides:

Freeze-dried (unreconstituted): This is the most stable form. It is best preserved by freezing and protecting it from moisture and light for long-term storage.
Reconstituted: once in solution, the peptide is less stable and must be kept refrigerated, being used within a short period; for extended storage, freezing in aliquots is usually preferred.
Avoid repeated freeze-thaw cycles, as they can degrade the peptide.

Given that the molecule is characterized by rapid enzymatic degradation in biological media, careful cold chain management is especially relevant.

Documented Survodutide security profile

The documented safety information in open sources for Survodutide is limited and should be interpreted with caution, also considering that it is research material and not for clinical use.

Targeting both receptors increases the risk of specific side effects. Gastrointestinal distress (nausea, vomiting) is highly common in models. The glucagon component can theoretically cause transient increases in heart rate or blood pressure if unmanaged.

Formal contraindications and adverse event rates are not available in the consulted literature, so no figures are reported.

Survodutide in a comparative context

Compared to Semaglutide (GLP-1 only), Survodutide is specifically designed to hit the liver harder through the glucagon receptor, making it a primary candidate for liver-focused metabolic research rather than just general obesity.

History and development of Survodutide

Developed as a direct response to the global NASH epidemic. While GLP-1 agonists help patients lose weight (which indirectly helps the liver), researchers created Survodutide to actively and directly strip fat from the liver tissue via the glucagon pathway.